Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration

Molecular Vision

Volumn 16, Issue , 2010, Pages 2598-2604

  Teper, Slawomir J ^a   Nowinska, Anna ^a   Pilat, Jaroslaw ^a   Palucha, Andrzej ^b   Wylegala, Edward ^a  

^a Okregowy Szpital Kolejowy ^*  (Poland)

^b Genomed   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; RANIBIZUMAB;

AGED; ARMS2 GENE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GENE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; TREATMENT RESPONSE; VISUAL ACUITY;

AGED; AMINO ACID SUBSTITUTION; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HUMANS; MACULAR DEGENERATION; MALE; REGRESSION ANALYSIS; RETINA; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 78650767139     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 2007; 297:1793-800. [PMID: 17456821]
2. Anderson DH, Radeke MJ, Gallo NB, Chapin EA, Johnson PT, Curletti CR, Hancox LS, Hu J, Ebright JN, Malek G, Hauser MA, Rickman CB, Bok D, Hageman GS, Johnson LV. The pivotal role of the complement system in aging and agerelated macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010; 29:95-112. [PMID: 19961953]
3. Kortvely E, Hauck SM, Duetsch G, Gloeckner CJ, Kremmer E, Alge-Priglinger CS, Deeg CA, Ueffing M. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest Ophthalmol Vis Sci 2010; 51:79-88. [PMID: 19696174]
4. Francis PJ, Zhang H, Dewan A, Hoh J, Klein ML. Joint effects of polymorphisms in the HTRA1, LOC387715/ARMS2, and CFH genes on AMD in a Caucasian population. Mol Vis 2008; 14:1395-400. [PMID: 18682806]
5. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and metaanalysis. Ophthalmology 2008; 115:116-26. [PMID: 17675159]
6. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116:57-65. [PMID: 19118696]
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-31. [PMID: 17021318]
8. Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005; 14:207-21. [PMID: 16301836]
9. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, Wolf S. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94:2-13. [PMID: 19443462]
10. Seitsonen SP, Jarvela IE, Meri S, Tommila PV, Ranta PH, Immonen IJ. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 2007; 17:943-9. [PMID: 18050121]
11. Brantley MA Jr, Edelstein SL, King JM, Plotzke MR, Apte RS, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative agerelated macular degeneration to photodynamic therapy. Eye (Lond) 2009; 23:626-31. [PMID: 18292785]
12. Chowers I, Meir T, Lederman M, Goldenberg-Cohen N, Cohen Y, Banin E, Averbukh E, Hemo I, Pollack A, Axer-Siegel R, Weinstein O, Hoh J, Zack DJ, Galbinur T. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis 2008; 14:2263-71. [PMID: 19065273]
13. Goverdhan SV, Hannan S, Newsom RB, Luff AJ, Griffiths H, Lotery AJ. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye 2008; 22:849-54. [PMID: 17464302]
14. Brantley MA Jr, Fang AM, King JM, Tewari A, Kymes SM, Shiels A. Association of complement factor H and LOC387715 genotypes with response of exudative age- related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007; 114:2168-73. [PMID: 18054635]
15. Lee AY, Raya AK, Kymes SM, Shiels A, Brantley MA Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009; 93:610-3. [PMID: 19091853]
16. Mataix J, Desco MC, Palacios E, Garcia-Pous M, Navea A. Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a longterm study. Ophthalmic Surg Lasers Imaging 2009; 40:277-84. [PMID: 19485292]
17. Ioannidis JP, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic variants on the design and interpretation of genetic association studies of complex diseases. Am J Epidemiol 2006; 164:609-14. [PMID: 16893921]